CD38 and Miyoshi myopathy: Though anti-CD38 mAbs are increasingly being incorporated into the upfront treatment of patients with transplant-eligible or -ineligible MM [22–25], these agents were not publicly reimbursed in the front-line setting in Canada during the study period.